TOPICYCLINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOPICYCLINE (TOPICYCLINE).
TOPICYCLINE is a synthetic tetracycline derivative that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine and feces. |
| Excretion | Renal: 70-80% unchanged; biliary/fecal: 10-15%; minor metabolism via CYP3A4. |
| Half-life | Terminal elimination half-life: 22-28 hours (mean 25 h). Clinical context: supports once-daily dosing; may be extended in renal impairment (CrCl <30 mL/min). |
| Protein binding | ~85% bound to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.8-1.2 L/kg (mean 1.0 L/kg). Clinical meaning: indicates moderate tissue penetration, with drug distributing into total body water and some tissue binding. |
| Bioavailability | Oral: 70-90% (mean 80%); topical (dermal): approximately 2-5% systemic absorption. |
| Onset of Action | Oral: 30-60 minutes; topical (dermal): 1-2 hours. |
| Duration of Action | Oral: 12-24 hours; topical: 12 hours. Clinical notes: longer duration supports QD dosing; topical duration may be extended with occlusive dressings. |
| Molecular Weight | 357.4 |
Adults: 100 mg orally twice daily, or 200 mg intravenously once daily.
| Dosage form | FOR SOLUTION |
| Renal impairment | GFR > 50 mL/min: no adjustment; GFR 30-50 mL/min: 75 mg orally twice daily; GFR < 30 mL/min: 50 mg orally twice daily; hemodialysis: 50 mg orally twice daily, on dialysis days administer after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | 2 mg/kg orally twice daily, maximum 100 mg per dose; or 4 mg/kg intravenously once daily, maximum 200 mg per dose. |
| Geriatric use | Start at 75 mg orally twice daily; monitor renal function and consider dose reduction due to age-related decline in GFR. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women. Animal studies have shown embryotoxicity at high doses. Use only if potential benefit justifies potential risk to the fetus. |
| 2nd trimester | Same as first trimester. Caution advised due to limited data. |
| 3rd trimester | Same as first trimester. Avoid near term due to theoretical risk of neonatal side effects. |
Clinical note
Comprehensive clinical and safety monograph for TOPICYCLINE (TOPICYCLINE).
| Placental transfer | Based on animal studies, the drug and/or its metabolites cross the placenta. Human data are insufficient to quantify extent. |
| Breastfeeding | Excretion into human milk is unknown. Due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to topicycline or any component of the formulationSerious hypersensitivity reactions (e.g., anaphylaxis) to tetracyclines
| Precautions | Photosensitivity reactions may occur; avoid prolonged sun exposure., Use during pregnancy may cause fetal harm; consider alternative therapy., Pseudomembranous colitis has been reported with antibacterial agents. |
| Food/Dietary | No significant food interactions. However, oral tetracyclines bind with dairy products; for topical use, this is negligible. Avoid sun exposure and tanning beds. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Topical tetracycline exposure in pregnancy is not associated with major congenital malformations. However, systemic use in second and third trimesters carries risk of dental discoloration and bone growth retardation in the fetus. Topical application has minimal systemic absorption, so risk is likely low, but avoidance is recommended during pregnancy, especially after the first trimester. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Observe for signs of maternal allergic or photosensitivity reactions. Inadvertent systemic exposure is minimal. |
| Fertility Effects | No evidence of adverse effects on fertility with topical tetracycline. Systemic absorption insufficient to impact reproductive function. |
| Topicycline is a topical tetracycline antibiotic used primarily for acne vulgaris. Apply a thin film to affected areas twice daily; avoid contact with eyes, nose, and mouth. It may cause temporary yellowing of skin or fabrics. Do not use in patients with hypersensitivity to tetracyclines. Its efficacy is comparable to oral tetracyclines with fewer systemic side effects. |
| Patient Advice | Apply a thin layer to clean, dry skin exactly as directed. · Avoid contact with eyes, lips, and mucous membranes; rinse with water if contact occurs. · May cause temporary yellow staining of skin or clothing; use old towels and pillowcases. · Do not use with other topical acne products unless directed by your doctor. · Do not take by mouth; for topical use only. · Inform your doctor if you are pregnant, breastfeeding, or planning to become pregnant. · Use sunscreen and protective clothing, as tetracyclines can increase sun sensitivity. · Do not use on broken or infected skin unless prescribed. |